Two Sigma Advisers
ITOS

Two Sigma Advisers’s iTeos Therapeutics ITOS Stock Holding History

Two Sigma Advisers’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,000
Closed -$179K – 2493
2025
Q2 		$179K Buy
+18,000
New +$145K ﹤0.01% 2141
2024
Q4 		– Sell
-37,900
Closed -$387K – 2432
2024
Q3 		$387K Buy
37,900
+19,700
+108% +$301K ﹤0.01% 1813
2024
Q2 		$270K Buy
+18,200
New +$261K ﹤0.01% 2113
2022
Q4 		– Sell
-86,200
Closed -$1.64M – 2609
2022
Q3 		$1.64M Sell
86,200
-69,000
-44% -$1.59M ﹤0.01% 1271
2022
Q2 		$3.2M Sell
155,200
-75,900
-33% -$1.8M 0.01% 973
2022
Q1 		$7.44M Buy
231,100
+51,100
+28% +$1.86M 0.02% 639
2021
Q4 		$8.38M Buy
180,000
+62,400
+53% +$2.08M 0.02% 562
2021
Q3 		$3.17M Buy
117,600
+78,900
+204% +$2.06M 0.01% 1011
2021
Q2 		$993K Buy
+38,700
New +$922K ﹤0.01% 1643

Other funds holding ITOS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Two Sigma Advisers's ITOS Position: Q3 2025 in Review

Two Sigma Advisers sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 18,000 shares — an estimated $179K sold.

Two Sigma Advisers first reported a position in ITOS in Q2 2021 and held it in 9 quarters. The position peaked at $8.38M in Q4 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

  • Two Sigma Advisers reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 18,000 iTeos Therapeutics shares in Q3 2025, an estimated $179K.
  • Two Sigma Advisers first reported a position in iTeos Therapeutics in Q2 2021 and held it in 9 quarters.
  • Two Sigma Advisers's iTeos Therapeutics position peaked at $8.38M in Q4 2021.
  • 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Two Sigma Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.